miR-34a directly targets tRNA<sub>i</sub><sup>Met</sup> precursors and affects cellular proliferation, cell cycle, and apoptosis.

Wang, Bo; Li, Dongping; Kovalchuk, Igor; Apel, Ingrid J; Chinnaiyan, Arul M; Wóycicki, Rafał K; Cantor, Charles R; Kovalchuk, Olga · Proc Natl Acad Sci U S A · 2018

basic_science · Level V

Where this comes from

Abstract

It remains unknown whether microRNA (miRNA/miR) can target transfer RNA (tRNA) molecules. Here we provide evidence that miR-34a physically interacts with and functionally targets tRNA<sub>i</sub><sup>Met</sup> precursors in both in vitro pulldown and Argonaute 2 (AGO2) cleavage assays. We find that miR-34a suppresses breast carcinogenesis, at least in part by lowering the levels of tRNA<sub>i</sub><sup>Met</sup> through AGO2-mediated repression, consequently inhibiting the proliferation of breast cancer cells and inducing cell cycle arrest and apoptosis. Moreover, miR-34a expression is negatively correlated with tRNA<sub>i</sub><sup>Met</sup> levels in cancer cell lines. Furthermore, we find that tRNA<sub>i</sub><sup>Met</sup> knockdown also reduces cell proliferation while inducing cell cycle arrest and apoptosis. Conversely, ectopic expression of tRNA<sub>i</sub><sup>Met</sup> promotes cell proliferation, inhibits apoptosis, and accelerates the S/G2 transition. Moreover, the enforced expression of modified tRNA<sub>i</sub><sup>Met</sup> completely restores the phenotypic changes induced by miR-34a. Our results demonstrate that miR-34a directly targets tRNA<sub>i</sub><sup>Met</sup> precursors via AGO2-mediated cleavage, and that tRNA<sub>i</sub><sup>Met</sup> functions as an oncogene, potentially representing a target molecule for therapeutic intervention.

Medical subject headings